Drug Trial Radar · NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
477
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Mar 28, 2029
Study completion Oct 27, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.
Conditions
- Colon Adenocarcinoma
- Rectal Adenocarcinoma
Interventions
CalderasibDrug
Oral tablet
OxaliplatinDrug
Per label
Leucovorin/levofolinate calciumDrug
Per label
5-FluorouracilDrug
Per label
CetuximabBiological
Per label
BevacizumabDrug
Per label
Bevacizumab biosimilarDrug
Per label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 44 months
- Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 44 months
- Progression Free Survival (PFS)Time frame: Up to approximately 44 months
Locations
247 sites in 29 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona ( Site 0090)
Phoenix, Arizona · Recruiting
Orange Coast Memorial Medical Center ( Site 2007)
Fountain Valley, California · Recruiting
Los Angeles Hematology Oncology Medical Group ( Site 0084)
Los Angeles, California · Recruiting
University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 2021)
Sacramento, California · Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 0088)
Santa Monica, California · Recruiting
University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087)
Fort Collins, Colorado · Recruiting
Rocky Mountain Cancer Centers (RMCC) ( Site 8000)
Lone Tree, Colorado · Recruiting
Florida Cancer Specialists - South ( Site 7002)
Fort Myers, Florida · Recruiting
Mayo Clinic in Florida ( Site 0092)
Jacksonville, Florida · Recruiting
Orlando Health Cancer Institute ( Site 0065)
Orlando, Florida · Recruiting
Florida Cancer Specialists - North ( Site 7001)
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists - East ( Site 7000)
West Palm Beach, Florida · Recruiting
Piedmont Atlanta Hospital ( Site 2002)
Atlanta, Georgia · Recruiting
Saint Alphonsus Regional Medical Center ( Site 0085)
Boise, Idaho · Recruiting
Endeavor Health ( Site 2027)
Evanston, Illinois · Recruiting
Accellacare of Duly ( Site 2015)
Lisle, Illinois · Recruiting
Franciscan Health ( Site 2025)
Indianapolis, Indiana · Recruiting
University of Iowa ( Site 0074)
Iowa City, Iowa · Recruiting
University of Kentucky ( Site 0055)
Lexington, Kentucky · Recruiting
Norton Cancer Institute, Audubon Hospital Campus ( Site 0054)
Louisville, Kentucky · Recruiting
University of Maryland ( Site 2016)
Baltimore, Maryland · Recruiting
Greater Baltimore Medical Center ( Site 0068)
Baltimore, Maryland · Recruiting
Mayo Clinic in Rochester, Minnesota ( Site 0091)
Rochester, Minnesota · Recruiting
Hattiesburg Clinic ( Site 0064)
Hattiesburg, Mississippi · Recruiting
Saint Luke's Cancer Institute ( Site 0082)
Kansas City, Missouri · Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 2000)
Billings, Montana · Recruiting
University Of Nebraska Medical Center ( Site 0078)
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 2026)
Las Vegas, Nevada · Recruiting
Renown Regional Medical Center ( Site 0056)
Reno, Nevada · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060)
Hackensack, New Jersey · Recruiting
Atlantic Health System ( Site 0093)
Summit, New Jersey · Recruiting
San Juan Oncology Associates, P.C ( Site 2011)
Farmington, New Mexico · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0095)
New York, New York · Recruiting
Ellis Hospital ( Site 0098)
Schenectady, New York · Recruiting
WakeMed Raleigh Campus ( Site 0094)
Raleigh, North Carolina · Recruiting
Miami Valley Hospital South ( Site 0075)
Centerville, Ohio · Recruiting
University of Cincinnati Medical Center ( Site 2005)
Cincinnati, Ohio · Recruiting
University of Toledo Medical Center ( Site 2001)
Toledo, Ohio · Recruiting
St. Luke's University Health Network ( Site 2014)
Easton, Pennsylvania · Recruiting
UPMC Hillman Cancer Center ( Site 2024)
Pittsburgh, Pennsylvania · Recruiting
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.